Ethynodiol Diacetate And Ethinyl Estradiol

Birth Control, Acne Vulgaris, Folate supplementation therapy + 5 more
Treatment
1 FDA approval
20 Active Studies for Ethynodiol Diacetate And Ethinyl Estradiol

What is Ethynodiol Diacetate And Ethinyl Estradiol

EthinylestradiolThe Generic name of this drug
Treatment SummaryEthinylestradiol is a synthetic form of the female hormone estrogen. It was created in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. Ethinylestradiol is more easily absorbed into the body when taken orally, making it a more effective form of estrogen. It has since replaced mestranol in contraceptive pills, and was approved by the FDA in 1943.
LOESTRIN Fe 1.5/30is the brand name
image of different drug pills on a surface
Ethynodiol Diacetate And Ethinyl Estradiol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
LOESTRIN Fe 1.5/30
Ethinylestradiol
1973
679

Approved as Treatment by the FDA

Ethinylestradiol, also known as LOESTRIN Fe 1.5/30, is approved by the FDA for 1 uses including Birth Control .
Birth Control
Used to treat Contraception in combination with Levonorgestrel

Effectiveness

How Ethynodiol Diacetate And Ethinyl Estradiol Affects PatientsEthinylestradiol is a synthetic form of estrogen that stops the body from releasing hormones that cause ovulation and thickening of the uterus lining. It is taken once daily and is generally considered safe, even if taken in higher doses than recommended. It is important to be aware of the risks of blood clots associated with taking this medication.
How Ethynodiol Diacetate And Ethinyl Estradiol works in the bodyEthinylestradiol is a synthetic form of the female hormone estrogen. It reduces bone density, suppresses ovulation, thickens cervical mucus, and prevents changes in the endometrium that would allow a fertilized egg to implant. It also lowers luteinizing hormone, making the endometrium less hospitable to a fertilized egg, and increases a protein called sex hormone binding globulin.

When to interrupt dosage

The volume of Ethynodiol Diacetate And Ethinyl Estradiol is contingent upon the diagnosed state, for example Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The measure of dosage depends on the procedure of administration as indicated in the table beneath.
Condition
Dosage
Administration
Birth Control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Acne Vulgaris
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Folate supplementation therapy
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Hormonal Contraception
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Osteoporosis
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Patient desires oral contraception for birth control
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral
Menopause
, 0.02 mg, 0.0025 mg, 0.03 mg, 0.0035 mg/hour, 0.005 mg, 2.7 mg, 0.035 mg, 0.6 mg, 2.6 mg, 0.05 mg, 0.5 mg, 0.75 mg, 0.025 mg, 0.0015 mg/hour, 0.04 mg, 0.01 mg, 1.0 mg, 0.075 mg, 0.105 mg, 0.07 mg, 0.1 mg, 0.75 mg/[USP'U], 0.0075 mg/hour, 17.4 mg, 0.085 mg, 2.3 mg
, Kit, Tablet - Oral, Oral, Tablet, Kit - Oral, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Insert, extended release, Vaginal, Insert, extended release - Vaginal, Ring - Vaginal, Ring, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Patch, Patch - Transdermal, Capsule, Capsule - Oral

Warnings

Ethynodiol Diacetate and Ethinyl Estradiol have twenty-six contraindications, hence should be avoided if you have any of the conditions documented in the following table.Ethynodiol Diacetate And Ethinyl Estradiol Contraindications
Condition
Risk Level
Notes
Smoking
Do Not Combine
Metrorrhagia
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Thrombophlebitis
Do Not Combine
Venous Thrombosis
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
Breast
Do Not Combine
Coronary Artery Disease
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Thromboembolism
Do Not Combine
Coronary Disease
Do Not Combine
Hypersensitivity
Do Not Combine
Pulse Frequency
Do Not Combine
Adrenal Insufficiency
Do Not Combine
major surgery with prolonged immobilization
Do Not Combine
Pulse Frequency
Do Not Combine
Hypertension
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Breast Cancer
Do Not Combine
Liver Neoplasms
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Fibrosis
Do Not Combine
Breast
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ethinylestradiol may interact with Pulse Frequency
Renal Insufficiency
Do Not Combine
There are 20 known major drug interactions with Ethynodiol Diacetate And Ethinyl Estradiol.
Common Ethynodiol Diacetate And Ethinyl Estradiol Drug Interactions
Drug Name
Risk Level
Description
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Ethinylestradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Ethinylestradiol.
Belinostat
Major
The metabolism of Belinostat can be increased when combined with Ethinylestradiol.
Binimetinib
Major
The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.
Ethynodiol Diacetate And Ethinyl Estradiol Toxicity & Overdose RiskWomen who take too much of this drug may experience bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. To treat an overdose, doctors will provide supportive care and keep an eye on potassium, sodium, and acid levels in the body.
image of a doctor in a lab doing drug, clinical research

Ethynodiol Diacetate And Ethinyl Estradiol Novel Uses: Which Conditions Have a Clinical Trial Featuring Ethynodiol Diacetate And Ethinyl Estradiol?

38 active studies are examining the potential of Ethynodiol Diacetate and Ethinyl Estradiol in providing Folate supplementation therapy, relieving Premenstrual Dysphoric Disorder and managing Menopausal symptoms.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Hormonal Contraception
0 Actively Recruiting
Folate supplementation therapy
0 Actively Recruiting
Patient desires oral contraception for birth control
0 Actively Recruiting
Osteoporosis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Menopause
0 Actively Recruiting

Patient Q&A Section about ethynodiol diacetate and ethinyl estradiol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Ethynodiol diacetate and ethinyl estradiol a combination pill?

"Ethinyl estradiol and ethynodiol diacetate is a combination birth control pill that contains female hormones that prevent ovulation."

Answered by AI

What is the difference between Kelnor and Zovia?

"Zovia and Ethynodiol have the same progestin to estrogen hormone ratio as Kelnor. However, Nortrel has a different progestin hormone (norethindrone) and the same amount of estrogen as Kelnor."

Answered by AI

Is ethynodiol diacetate a progestin?

"After ovulation, the egg travels through the fallopian tube to the uterus. The egg can be fertilized by a sperm cell during this time and pregnancy may occur.

Ethynodiol Diacetate works by thickening the mucus around the cervix. This mucus blocks sperm from getting through to the egg. Ethynodiol Diacetate also alters the lining of the uterus. This makes it harder for a fertilized egg to implant itself in the uterus and start a pregnancy.

Ethynodiol Diacetate is used as a female contraceptive. It is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). After ovulation, the egg travels through the fallopian tube to the uterus. The egg can be fertilized by a sperm cell during this time and pregnancy may occur.

Ethynodiol Diacetate works by thickening the mucus around the cervix. This mucus blocks sperm from getting through to the egg. Ethynodiol Diacetate also alters the lining of the uterus. This makes it harder for"

Answered by AI

What does ethinyl estradiol do to your body?

"Levonorgestrel and ethinyl estradiol combination is a contraceptive that prevents pregnancy by inhibiting ovulation."

Answered by AI

Clinical Trials for Ethynodiol Diacetate And Ethinyl Estradiol

Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Image of EmpoweRx, Inc in Del Mar, United States.

HAPPI Software for Birth Control Access

18+
All Sexes
Del Mar, CA
The goal of this clinical trial is to learn if use of the HAPPI software can improve pharmacist-provided birth control services. The main questions it aims to answer are: 1. Does the HAPPI software make it easier for pharmacists to provide birth control services in their pharmacy? 2. Does the HAPPI software make it easier for patients to access birth control? Researchers will compare pharmacists' implementation and patients' access when using the HAPPI software and when not using the HAPPI software to see if the software improves implementation and access. Participants will include pharmacists and patients. Pharmacists will be asked to provide birth control services as normal while using the HAPPI software. Patients will be asked to receive birth control services from a pharmacist as normal, while using the HAPPI software.
Recruiting
Has No Placebo
EmpoweRx, Inc
Image of Calabasas Pharmacy in Calabasas, United States.

Electronic Health Record Platform for Birth Control

18 - 51
Female
Calabasas, CA
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Waitlist Available
Has No Placebo
Calabasas Pharmacy (+4 Sites)OvaryIt, LLC
Have you considered Ethynodiol Diacetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Ethynodiol Diacetate And Ethinyl Estradiol, we think they might fit your search criteria.Go to Trials
Image of Jackson State University/Department of Behavioral & Environmental Health in Jackson, United States.

PEN-3 Intervention for Postpartum Depression

18 - 45
Female
Jackson, MS
Maternal mortality in the United States is higher than in peer nations and has not decreased since 1990. Beyond mortality, severe maternal mortality impacts far too many women. Not only are these high rates alarming, but notable racial/ethnic and socioeconomic disparities exist. These inequities are highly regional, with women living in the rural southeast part of the United States, including the Mississippi Delta, having the highest rates of maternal mortality and morbidity. Unfortunately, these disparities have proven to be stubbornly resistant to interventions, necessitating an innovative multifaceted approach focused on community practice, building trust, and prioritizing patient voices. To meet this need, this proposal aims to establish the Mississippi Delta Research Center of Excellence for Maternal Health with the goal of addressing preventable maternal mortality, decreasing severe maternal morbidity, and promoting maternal health equity in partnership with the Mississippi Delta community. This patient-clinical linkages intervention study will evaluate the effectiveness of a multilevel and multisector communication and health literacy strategy to increase trust and engagement in postpartum healthcare among women in the Mississippi Delta, with a specific focus on Black women, their families, and their communities. These research projects both have the overarching goal of partnering with the community to determine and meet the needs of pregnant and postpartum women in the Mississippi Delta and address the disparities within maternity health and health care outcomes.
Recruiting
Has No Placebo
Jackson State University/Department of Behavioral & Environmental HealthMary Shaw, PhD
Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Birth Control Pills and DNA Interaction

18 - 45
Female
Aurora, CO
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these birth control pills work to prevent pregnancy. The investigators are also interested in exploring how these differences in our DNA can also explain why patients taking the exact same formulation of birth control pill will experience very different side effects. The main questions it aims to answer are: * Do individuals with the CYP3A7\*1C variant have increased metabolism of both desogestrel and ethinyl estradiol when taking a combined oral contraceptive pill? * Do individuals with the CYP3A7\*1C variant experience higher rates of breakthrough ovulation while taking a desogestrel/ethinyl estradiol combined oral contraceptive pill? * What novel genetic loci are associated with alterations in steroid hormone pharmacokinetics and pharmacodynamics among a larger cohort of combined oral contraceptive pill users? Participants will take a specific formulation of combined oral contraceptive pill (desogestrel/ethinyl estradiol) and undergo the following procedures: * Blood draw to measure the amount of progestin and estrogen in their system from the combined oral contraceptive pill * Questionnaires to assess side effects possibly caused by the combined oral contraceptive pill * Blood draw to measure endogenous hormone levels and biomarkers that may be affected by the combined oral contraceptive pill * A transvaginal ultrasound to measure any ovarian follicles (optional procedure)
Phase 4
Recruiting
University of Colorado Anschutz Medical Campus (+2 Sites)Aaron M Lazorwitz, MD, PhD
Have you considered Ethynodiol Diacetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Ethynodiol Diacetate And Ethinyl Estradiol, we think they might fit your search criteria.Go to Trials
Image of Greater Boston Health Center in Boston, United States.

SBIRT for Alcohol and Substance Use Disorders

18+
All Sexes
Boston, MA
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: * Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? * Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? * Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Recruiting
Has No Placebo
Greater Boston Health Center (+3 Sites)Kelli S Hall, MD
Image of OHSU in Portland, United States.

Progestin Contraceptives for Birth Control Effects

18 - 40
Female
Portland, OR
The purpose of the study is to learn more about menstrual changes in progestin contraception users. The investigators are hoping to find out what changes in the endometrium lead to different bleeding patterns during the first year of progestin contraception use. Participants will choose to receive the contraceptive implant (Etonogestrel implant also called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy tests. Participants will also use a daily text message or email diary to report bleeding patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the entire endometrium using single-cell RNA seq data (sCRNAseq).
Phase < 1
Recruiting
OHSUAlison Edelman, MD
Have you considered Ethynodiol Diacetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Ethynodiol Diacetate And Ethinyl Estradiol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security